Anti-PD-1/PD-L1 immunotherapy can attenuate the immunosuppression against T cell surveillance in tumor patients; however, it hardly eliminates the resistant tumor cells, which can evade the clearance of the immune system by up-regulating PD-L1 expression (Vesely et al., 2011; Oliveira et al., 2019). Here, CD274 is linked to neoplasm.